9.57

0.62% -0.06

After Hours: 9.57

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $9.57, with a volume of 2.03M. It is down -0.62% in the last 24 hours and up +7.65% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Previous Close:

$9.63

Open:

$9.41

24h Volume:

2.03M

Relative Volume:

1.07

Market Cap:

$990.66M

Revenue:

Net Income/Loss:

$-129.47M

P/E Ratio:

-6.3185

EPS:

-1.5146

Net Cash Flow:

$-114.08M

1W Performance:

-0.83%

1M Performance:

+7.65%

6M Performance:

-22.70%

1Y Performance:

+67.89%

1-Day Range:

$9.135

$9.64

1-Week Range:

$9.135

$10.12

52-Week Range:

$4.52

$14.93

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

104

Twitter

Next Earnings Date

2026-05-04

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC Oric Pharmaceuticals Inc	9.57	996.87M	0	-129.47M	-114.08M	-1.5146
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Piper Sandler	Overweight
Nov-20-25	Initiated	Evercore ISI	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-04-25	Resumed	Guggenheim	Buy
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Oct-31-24	Initiated	Wells Fargo	Overweight
Sep-06-24	Initiated	Stifel	Buy
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

12:37 PM

Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00 - MarketBeat

12:37 PM

07:43 AM

ORIC Pharmaceuticals Q1 2026 Financial Report and Forward-Looking Statements - Minichart

07:43 AM

01:14 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire

01:14 AM

May 04, 2026

ORIC Pharmaceuticals (NASDAQ: ORIC) lifts cash to $419.7M as R&D ramps - Stock Titan

May 04, 2026

Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

May 04, 2026

ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 04, 2026

ORIC (NASDAQ: ORIC) details Q1 2026 loss and Phase 3 cancer plans - Stock Titan

May 04, 2026

Cancer drug developer picks Phase 3 dose, has cash into late 2028 - Stock Titan

May 04, 2026

BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million - TradingView

May 04, 2026

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - GlobeNewswire

May 04, 2026

May 03, 2026

(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily

May 03, 2026

May 02, 2026

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

May 02, 2026

May 01, 2026

Four new ORIC hires receive 216,000 options and 35,000 RSUs - Stock Titan

May 01, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out - ACCESS Newswire

May 01, 2026

2026-05-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | NDAQ:ORIC | Press Release - Stockhouse

May 01, 2026

Apr 30, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire

Apr 30, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Apr 30, 2026